Arena Pharmaceuticals pulled the plug on its application for approval of the obesity drug Belviq with European regulators, another blow to the commercial and regulatory effort behind the treatment. The San Diego-based biotech revealed the decision to withdraw the app in its first-quarter financial report late Thursday afternoon.
The FDA has given a green light to Vivus to start marketing its weight drug Qnexa, firing the starting pistol in a race to commercialize one of the first new obesity drugs in 13 years.
Orexigen ($OREX) says that it's enrollment of patients in a closely-watched safety study of its weight drug Contrave is happening much faster than expected.
Biotech investors have a busy FDA schedule to ponder for the month ahead. Adam Feuerstein at TheStreet highlights four big drug decisions in the weeks to come, and he's bullish about the chances of some closely-watched drugs.
More than a year of second-guessing and harsh criticism for Arena Pharmaceuticals concluded with a big victory for the drug developer, which earned an FDA approval for lorcaserin, the first new weight drug to hit the U.S. market in 13 long years.
The biotech investment community is on high alert today, waiting for word of the FDA's formal decision on Arena Pharmaceutical's application for its weight drug lorcaserin.
A committee of non-agency advisers backed approval of the weight drug, lorcaserin, which went down in flames when last in front of the same panel in 2010.
Biotech industry watchers are paying close attention to an FDA advisory committee today that will judge the biotech's drug, lorcaserin.
Oddsmakers are watching the FDA advisory committee that will consider lorcaserin this week very closely.
Shares of Vivus slid more than 6% after the news spread that the FDA would delay a final decision on its closely watched application for the weight drug Qnexa.